Walgreens to stock kaléo’s Auvi-Q epinephrine injector
In an effort it said would improve access to epinephrine auto-injectors, Walgreens and kaléo are partnering to make the Richmond, Va.-based drug makers Auvi-Q auto-injectors available through Walgreens locations nationwide.
Walgreens will stock both the 0.15- and 0.3-mg dosage strength Auvi-Q injectors, which patients who are commercially insured and meet eligibility criteria can obtain at no cost through kaléo’s Auvi-Q AffordAbility program. Additionally, eligible patients who do not have insurance or prescription drug coverage might be able to gain support as well, the companies said.
“The health and wellbeing of our customers is of the upmost importance,” said Richard Ashworth, Walgreens president of operations. “Walgreens pharmacists continue to care for and work with patients and their prescribers to ensure they have access to the epinephrine auto-injectors they need, and we’re pleased to work with kaléo to help meet the demand for epinephrine auto-injectors across the country.”
Auvi-Q distinguishes itself from other anaphylaxis-treating auto-injectors by including voice instructions that help guide a user through the process of delivering epinephrine, as well as an auto-retracting needle system.
“Thanks to this collaboration with Walgreens, any patient who is having difficulty filling a prescription for an epinephrine auto-injector now has the opportunity to get Auvi-Q through Walgreens,” said Phil Rackliffe, general manager of allergy and pediatrics at kaléo. “We are working with insurance providers to maximize coverage of Auvi-Q for as many patients as possible.”
The companies also noted that patients who are unable to fill their current epinephrine prescriptions can have a Walgreens pharmacist work with their healthcare provider to determine whether Auvi-Q might be right for them.
Walgreens will stock both the 0.15- and 0.3-mg dosage strength Auvi-Q injectors, which patients who are commercially insured and meet eligibility criteria can obtain at no cost through kaléo’s Auvi-Q AffordAbility program. Additionally, eligible patients who do not have insurance or prescription drug coverage might be able to gain support as well, the companies said.
“The health and wellbeing of our customers is of the upmost importance,” said Richard Ashworth, Walgreens president of operations. “Walgreens pharmacists continue to care for and work with patients and their prescribers to ensure they have access to the epinephrine auto-injectors they need, and we’re pleased to work with kaléo to help meet the demand for epinephrine auto-injectors across the country.”
Auvi-Q distinguishes itself from other anaphylaxis-treating auto-injectors by including voice instructions that help guide a user through the process of delivering epinephrine, as well as an auto-retracting needle system.
“Thanks to this collaboration with Walgreens, any patient who is having difficulty filling a prescription for an epinephrine auto-injector now has the opportunity to get Auvi-Q through Walgreens,” said Phil Rackliffe, general manager of allergy and pediatrics at kaléo. “We are working with insurance providers to maximize coverage of Auvi-Q for as many patients as possible.”
The companies also noted that patients who are unable to fill their current epinephrine prescriptions can have a Walgreens pharmacist work with their healthcare provider to determine whether Auvi-Q might be right for them.